Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Public ClinicalTrials.gov record NCT05891171. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Study identification
- NCT ID
- NCT05891171
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Advanced Cancer
- Advanced Malignancies
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer (GEJ)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Triple Negative Breast Cancer (TNBC)
Interventions
- AB598 Drug
- Fluorouracil Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Zimberelimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2023
- Primary completion
- Feb 28, 2026
- Completion
- Feb 28, 2026
- Last update posted
- Mar 30, 2026
2023 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Lake City Cancer Care, LLC. | Lake City | Florida | 32024 | — |
| Affinity Health Hope and Healing Cancer Services, LLC | Hinsdale | Illinois | 60521 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Gabrail Cancer Center (GCC) Canton Facility | Canton | Ohio | 44718 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Next Oncology Dallas | Irving | Texas | 75039 | — |
| Next Oncology Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05891171, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05891171 live on ClinicalTrials.gov.